You are here

Article Text

Article menu
Download PDFPDF
Electronic pages
Reply to: Very early rheumatoid arthritis as a predictor of remission: a multicentre real life prospective study
  1. Henning Zeidler
  1. Correspondence to Professor Henning Zeidler, Emeritus, Medizinische Hochschule, Hannover Wolfsburger Damm 26c, Hannover 30625, Germany; henningzeidler{at}aol.com

https://doi.org/10.1136/annrheumdis-2012-202480

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Gremese et al conclude from the real-life prospective study performed in three early arthritis clinics, that 12 weeks disease duration, and an early intervention with disease-modifying antirheumatic drugs (DMARD), represent the most significant opportunities to reach remission of rheumatoid arthritis (RA). Moreover, it is supposed that vera early RA (VERA) represents a window of opportunity in terms of cost saving.1

    A high level of confidence in the diagnosis of RA early in its course is mandatory for the validity of any study. Nevertheless, experts often disagree about diagnoses, and discrepancies may …

    View Full Text

    Footnotes

    • Competing interests None.

    • Provenance and peer review Not commissioned; internally peer reviewed.

    • Correction notice This article has been corrected since it was published online first. Changes have been made to the text, and to the correspondence details.